MPM BioImpact’s Praxis Precision Medicines PRAX Stock Holding History

MPM BioImpact’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-40,667	Closed	-$1.45M	–	33
2022 Q4	$1.45M	Buy	+40,667	New	+$1.27M	0.38%	29

Other funds holding PRAX

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TLP

Tri Locum Partners New York $813M AUM 101.01% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

MPM BioImpact's PRAX Position: Q1 2023 in Review

MPM BioImpact sold out of Praxis Precision Medicines (PRAX) in Q1 2023, closing a stake of 40,667 shares — an estimated $1.45M sold.

MPM BioImpact first reported a position in PRAX in Q4 2022 and held it in 1 quarter. The position peaked at $1.45M in Q4 2022. 86 funds tracked by Wall St. Rank hold PRAX as of Q1 2023.

MPM BioImpact reported no remaining Praxis Precision Medicines position as of Q1 2023 after selling out during the quarter.
MPM BioImpact sold 40,667 Praxis Precision Medicines shares in Q1 2023, an estimated $1.45M.
MPM BioImpact first reported a position in Praxis Precision Medicines in Q4 2022 and held it in 1 quarter.
MPM BioImpact's Praxis Precision Medicines position peaked at $1.45M in Q4 2022.
86 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2023.

Based on MPM BioImpact's 13F filing for Q1 2023, filed 12 May 2023.